Shilpa Pharma

Full-spectrum peptide CDMO offering SPPS, LPPS, hybrid, recombinant, and native chemical ligation synthesis. cGMP peptide manufacturing from preclinical to commercial scale. Advanced modifications including lipidation, PEGylation, cyclization, and disulfide bridging.

Shilpa Pharma is listed as a CDMO in the peptide supply chain, serving Asia markets from India. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is based on publicly available information and cross-referenced against industry databases. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.